← Home
Unlimited
Demo Account
AI Pipeline Architecture
Becky AI
Bioinformatics
Cheminformatics
Neuroinformatics
Clinical Intel
Formulation
Protein Network
Gene Expression
Mol. Docking
MD Simulation
Solubility
MRI/fMRI Data
PET Scans
EEG Data
IND Filing
Patent Strategy
Nanoparticle
Bioavailability
Shelf Life
0:00 / ~5:20
13/13 stages complete

Processing Pipeline

1

Human Protein Network

10s

2

Molecular Docking

20s

3

Docking Reasoning Agent

10s

4

Molecular Dynamics

30s

5

Toxicity Prediction

20s

6

Dissolving Agent

20s

7

Shelf Life

15s

8

Nanoparticle Size

15s

9

Lipid Bioavailability

20s

10

Excipients Risk Quality Control

20s

11

Cancer Reasoning Agent

25s

12

Chemical Patent Reasoning Agent

25s

13

IND Application Agent

30s

Analysis Results

#
Analysis Stage
Status
Summary
Confidence
Visualization
Docs
1
Human Protein Network
Complete
Identified 2 high-affinity protein targets: PIM1 and RSK2
94%
2
Molecular Docking
Complete
Strong binding affinity to PIM1 (4XH6) and RSK2 (4GUE) active sites
91%
3
Docking Reasoning Agent
Complete
Analyzed functional groups for binding contribution and modifiability
94%
4
Molecular Dynamics
Complete
Stable complex formation over 100ns simulation trajectory
88%
5
Toxicity Prediction
Complete
Low toxicity profile with favorable safety margins
96%
6
Dissolving Agent
Complete
Optimal solubility in ethanol and DMSO systems
93%
7
Shelf Life
Complete
Eudragit polymer provides optimal 24+ month stability
91%
8
Nanoparticle Size
Complete
Optimal particle size of 95nm achieved with Acetone-TPGS
88%
9
Lipid Bioavailability
Complete
Phospholipid complex increases bioavailability 3-5x
94%
10
Excipients Risk Quality Control
Complete
Minor stability concerns under UV exposure identified
85%
11
Cancer Reasoning Agent
Complete
Significant activity against colorectal and pancreatic cancer lines
92%
12
Chemical Patent Reasoning Agent
Complete
Generated 8 patent claims covering pharmacophore model and therapeutic applications
96%
13
IND Application Agent
Complete
Botanical IND application draft prepared per FDA guidance (89% complete)
89%

Full Analysis Report

Generate a PDF with all 13 stage results for Cannflavin A